Hormonal agents dominate the treatment landscape for prostate cancer and are routinely used in all lines of therapy. Next-generation hormonal treatments have expanded beyond metastatic castrate-…
Approximately 40% of gastric and gastroesophageal junction (GEJ) adenocarcinoma patients present with metastasis, and half of patients with localized disease progress to metastatic disease…
Marketed DMTs for multiple sclerosis deliver a high level of efficacy in preventing relapses and relapse-associated worsening of disability (RAW). However, MS patients still experience disability…
Pancreatic adenocarcinoma is an aggressive malignancy associated with an extremely poor prognosis and high lethality. The metastatic setting is the largest drug-treatable population in pancreatic…
Although tumor necrosis factor-alpha (TNF-α) inhibitors remain the most widely prescribed biologics for rheumatoid arthritis (RA) patients refractory to conventional DMARD treatment (the first-…
Generalized-onset seizures (GOS) simultaneously affect both sides of the brain and rapidly engage bilaterally distributed networks. Nearly 40% of the diagnosed epilepsy population presents with…
Systemic lupus erythematosus (SLE) is an autoimmune disease that can affect different organ systems of the body and manifest in a wide range of clinical symptoms, from general fatigue to serious…
Eosinophilic esophagitis (EoE) is a chronic, allergic inflammatory disease of the esophagus, characterized by an accumulation of eosinophils. It can cause difficulty with swallowing food and has…
The treatment of rheumatoid arthritis (RA) typically begins with cost-effective conventional DMARDs (cDMARDs), such as methotrexate or hydroxychloroquine. For patients who fail cDMARD treatment or…
Long-acting beta2 agonist (LABA) / long-acting muscarinic antagonist (LAMA) fixed-dose combinations (FDCs) have been gaining traction in the chronic obstructive pulmonary disease (COPD) market,…
Renal anemia is a common complication of chronic kidney disease (CKD). Although treatments—such as iron therapies, erythropoiesis-stimulating agents (ESAs), and HIF-PH inhibitors—are available…
Treatment of psoriatic arthritis (PsA) typically begins with conventional DMARDs, such as methotrexate, and progresses to more-potent biologics and/or targeted oral therapies as needed. The U.S…
The rising rates of antimicrobial resistance (AMR) have created an emergent need for development and discovery of antibiotics with activity against drug-resistant gram-negative pathogens (GNPs)…
Attention-deficit/hyperactivity disorder (ADHD) is one of most common pediatric disorders and one that can continue into adulthood. For decades, pediatric ADHD has been treated primarily with…
The launch of several novel therapies and multiple label expansions for premium-priced agents will fuel significant growth of the non-Hodgkin’s lymphoma (NHL) / chronic lymphocytic leukemia (CLL…